Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

By Zacks Equity Research | July 23, 2025, 9:57 AM

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Latest News

10 hours	What Insmed Stock's Premium Is Actually Buying VRTX Trefis
Aug-06	Zai Lab Ltd (ZLAB) (Q2 2026) Earnings Call Highlights: Global Biopharma Inflection Point with U. ... ZLAB +13.66% GuruFocus.com
Aug-06	Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates ZLAB +13.66% Business Wire
Aug-06	AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ... VRTX GuruFocus.com
Aug-04	Vertexs biggest overhang: a rival 50 times smaller VRTX BioPharma Dive
Aug-04	Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ... VRTX GuruFocus.com
Aug-03	Vertex Raises 2026 Guidance, But Shares Fall For One Key Reason VRTX Investor's Business Daily
Aug-03	Vertex: Q2 Earnings Snapshot VRTX Associated Press
Aug-03	Vertex Reports Second Quarter 2026 Financial Results VRTX Business Wire
Aug-03	U.S. FDA Grants Orphan Drug Designation to Zai Labs DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) ZLAB Business Wire
Aug-03	Palantir and other companies set to report earnings VRTX MarketWatch
Jul-31	Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? VRTX Trefis
Jul-29	AbCellera, Vertex partner on next-gen T-cell engagers VRTX BioPharma Dive
Jul-29	AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions VRTX Business Wire
Jul-23	Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor VRTX FinanceWire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)